IFN-gamma

Overview

Interferon-gamma (IFN-γ, type II interferon) is one of the three canonical signals — with TLR7 ligands and IL-21 — that drive naive B cells into the DN2 / atypical B cell pathway. It is the licensing signal of the three: it does not by itself make B cells divide, but it reprograms them so that the other two signals become far more effective.

Background context (not sourced to an ingested paper): IFN-γ signals through IFNGR1/IFNGR2 and STAT1. The wiki has no ingested source describing IFNGR or STAT1 in B cells directly, so neither has its own page; STAT1 appears only as a pathway-analysis prediction.

This page was created 2026-08-18. Before that, IFN-γ was one of the wiki’s largest structural gaps — named on ~15 pages and central to the DN2 model, with no page of its own. Its content had been scattered across T-bet, IL-21, ATF3 and CXCR3.

Key Points from Literature

IFN-γ is obligate for forming the T-bet^hi^ pre-ASC

• In “all minus one” human cultures, omitting BAFF, IL-2 or IL-21 barely changed T-bet⁺IRF4⁺ induction, but omitting IFN-γ left >80% of cells T-bet^neg/lo^ and they failed to upregulate IRF4 (see Zumaquero2019 - IFN-gamma Programs T-bet-hi B Cells for ASC Differentiation, human in vitro, ≥3 experiments)
• IFN-γ-producing Th1 helpers drove ~50% of healthy-donor B cells to express T-bet; Th2 helpers drove <3% (see Zumaquero2019 - IFN-gamma Programs T-bet-hi B Cells for ASC Differentiation, human MLR co-culture, n>30 co-cultures)
• Stimulating naive B cells with R848 + cytokines + IFN-γ but not IL-4 produced plasma cell differentiation with increased T-bet and CD11c and loss of CD21 and CD23 (see Sanz2019 - Consistent Classification of Human B Cell Populations, review, adapted from Jenks2018)
• IL-4 and IFN-γ exert reciprocal control over T-bet⁺ B cell differentiation (see Sanz2019 - Consistent Classification of Human B Cell Populations, review; consistent with the IL-4 conditional antagonism in Cancro2020 - Age-Associated B Cells, review, murine)

★ Timing: IFN-γ acts in a discrete early priming window

• IFN-γ is required during days 0–3 (“priming”). Eliminating it from the first 3 days prevented pre-ASC formation and left ASCs essentially undetectable; supplying it only during priming matched continuous exposure (see Zumaquero2019 - IFN-gamma Programs T-bet-hi B Cells for ASC Differentiation, human in vitro)
• IFN-γ is not itself a B cell mitogen and is reported to induce apoptosis in human B cells — yet it synergizes with TLR7/8 to permit multiple rounds of proliferation (see Zumaquero2019 - IFN-gamma Programs T-bet-hi B Cells for ASC Differentiation)

★ Mechanism: sensitization via epigenetic remodeling and IL-21R upregulation

• IFN-γ sensitizes B cells to subthreshold TLR7/8 signals: at 0.1 µg/ml R848 (100-fold below the saturating dose) proliferation occurred only with IFN-γ, and ASC frequency was ~10-fold higher (see Zumaquero2019 - IFN-gamma Programs T-bet-hi B Cells for ASC Differentiation)
• ATAC-seq at day 3 identified 15,917 differentially accessible regions. IFN-γ enriched accessibility around T-bet motifs; combined with IL-2 it produced the greatest enrichment around T-bet, STAT5, NF-κB p65, REL, IRF4 and BLIMP1 motifs (see Zumaquero2019 - IFN-gamma Programs T-bet-hi B Cells for ASC Differentiation, n=2–3/group)
• IFN-γ remodels the PRDM1 locus (4 differentially accessible regions, 3 of which are also present in SLE patient DN2 cells) and the IL21R locus (a region containing two putative T-bet motifs, seen only in IFN-γ-exposed cells and also present in SLE DN2 cells) (see Zumaquero2019 - IFN-gamma Programs T-bet-hi B Cells for ASC Differentiation)
• IL-21R protein rose 5.5–6-fold by day 6 in B cells that saw IFN-γ during the first 3 days, and IL-21-induced phospho-STAT3 was significantly increased in those cells (see Zumaquero2019 - IFN-gamma Programs T-bet-hi B Cells for ASC Differentiation). See IL-21R and STAT3.

IFN-γ in patients

• Plasma IFN-γ correlated with T-bet^hi^ DN2 frequency in SLE (Spearman r=0.495, p<0.05), as did the IFN-γ-induced cytokines CXCL10 (r=0.798), IL-6 (r=0.797) and TNFα (r=0.773); IFN-γ, CXCL10 and TNFα were all elevated versus healthy donors (see Zumaquero2019 - IFN-gamma Programs T-bet-hi B Cells for ASC Differentiation, n=20 HD, 40 SLE)

• Two IFN-γ-inducible proteins, CXCR3 and T-bet, are more highly expressed on circulating B cells from SLE patients than healthy controls (see Zumaquero2019 - IFN-gamma Programs T-bet-hi B Cells for ASC Differentiation, review of prior work in its introduction). See CXCR3.

• IFN-γ is named as one of the cytokines Tfh cells are inferred to deliver in proximity to developing T-bet⁺CD11c⁺ B cells, though the effector molecules were not directly tested (see Song2022 - Tfh Outside Germinal Centers Drive T-bet CD11c B Cells, murine)

• ABCs are reported to produce IFN-γ themselves, at levels higher than follicular B cells (see Cancro2020 - Age-Associated B Cells, review, murine — sole source; see Atypical B Cell Effector Output)

• ★ IFN-γR signalling — not T-bet — is the route to the plasma-cell programme. Ifngr1^−/−^ Be1 cells show significantly reduced Prdm1 at day 2, keep Prdm1/Irf4/Pou2af1/Xbp1 low through day 4, form almost no CD138⁺CD93⁺ ASC (15.3% → 0.6%) and secrete no antibody. Deleting Tbx21 in the same system leaves day-2 Prdm1 and Blimp-1-motif chromatin accessibility unchanged. Knocking out the receptor kills the PC programme; knocking out the transcription factor does not (see Stone2019 - T-bet Promotes ASC Differentiation by Limiting IFN-gamma Inflammation, mouse, Be1/Be2 co-culture + ATAC-seq + qPCR). See BLIMP-1.

• IFN-γ is simultaneously the ASC-licensing signal and the source of the brake that must be released. The IFN-γ-induced gene programme in B cells is bifunctional: it initiates Prdm1 upregulation but also initiates an inflammatory programme (NF-κB, TLR, STAT/IRF) that, if not restrained, prevents ASC formation. T-bet’s role is to restrain the second arm (see Stone2019 - T-bet Promotes ASC Differentiation by Limiting IFN-gamma Inflammation, mouse). This is a sharper reading of IFN-γ’s role than “amplifier” alone and complements the human licensing mechanism in Zumaquero2019 - IFN-gamma Programs T-bet-hi B Cells for ASC Differentiation (same lab).

• T-bet represses Ifng and Ifngr2, breaking an autocrine inflammatory loop. Both loci carry T-bet-motif-containing differentially accessible regions; Tbx21^−/−^ Be1 cells produced more IFN-γ and IL-6 after TLR7/9 + anti-CD40/anti-Ig stimulation (see Stone2019 - T-bet Promotes ASC Differentiation by Limiting IFN-gamma Inflammation, mouse, ATAC-seq + cytokine ELISA). B-cell-derived IFN-γ is therefore a feedforward risk that the T-bet programme actively contains.

Contradictions & Debates

★ Obligate for DN2, but not for human antibody responses generally. Zumaquero2019 - IFN-gamma Programs T-bet-hi B Cells for ASC Differentiation is explicit that IFN-γ is not required for human ASC formation as such — human B cells differentiate without it, and STAT1-deficient patients mount vaccine responses. Its own data show IFN-γ is worth a 5–10-fold amplification where TLR ligands are present. Wiki text should say “obligate for the T-bet^hi^ pre-ASC in this system,” not “required for antibody production.”

Same input, opposite fate. IFN-γ + TLR7 + CD40 has been reported to drive Bcl6 upregulation and a germinal-centre-like phenotype (Jackson et al. 2016, cited by Zumaquero2019 - IFN-gamma Programs T-bet-hi B Cells for ASC Differentiation, not ingested), the opposite of the EF/ASC fate seen without CD40. This is consistent with Jenks2018 - DN2 B Cells and EF Pathway in SLE’s finding that CD40L inhibits EF differentiation. Held as a hypothesis about the CD40 axis, not a wiki claim.

Is type I IFN interchangeable? IFNα also correlated with DN2 frequency (r=0.493), and Zumaquero2019 - IFN-gamma Programs T-bet-hi B Cells for ASC Differentiation notes considerable overlap between IFNα- and IFN-γ-regulated genes and suggests both may augment TLR7 signalling similarly. This matters greatly for dengue, whose early response is dominated by type I IFN and not IFN-γ (see Kwissa2014 - Monocytes Drive Plasmablast Differentiation in Dengue). Untested. See Type I Interferon.

Related Pages

T-bet, Type I Interferon, IL-21, IL-21R, STAT3, TLR7, CXCR3, ATF3, IRF4, BLIMP-1, Toll-like Receptor Signaling in B Cells, Extrafollicular T Cell Help, B Cell Receptor Signaling, DN2 B Cell, Atypical B Cell Effector Output

Sources

• Zumaquero2019 - IFN-gamma Programs T-bet-hi B Cells for ASC Differentiation
• Jenks2018 - DN2 B Cells and EF Pathway in SLE
• Sanz2019 - Consistent Classification of Human B Cell Populations
• Sanz2025 - Human Atypical B Cells Overview
• Cancro2020 - Age-Associated B Cells
• Song2022 - Tfh Outside Germinal Centers Drive T-bet CD11c B Cells
• Scharer2019 - Epigenetic Programming in SLE B Cells
• Lamprinou2026 - ABCs and DN B Cells
• Kwissa2014 - Monocytes Drive Plasmablast Differentiation in Dengue
• Stone2019 - T-bet Promotes ASC Differentiation by Limiting IFN-gamma Inflammation — mouse mechanism; IFN-γR required for the PC programme, T-bet-independently